Loading...
Given that disease-specific survival rates for patients with clinical stage I nonseminomatous germ-cell testicular cancer (NSGCT) are higher than 98%, investigators are striving to reduce therapy-related morbidity without compromising outcomes. Clinicians have used various prognostic factors to distinguish between high-risk patients (who might receive either primary retroperitoneal lymph node dissection or adjuvant chemotherapy) and low-risk patients (who might undergo surveillance).
To test the usefulness of risk-adapted NSGCT management in a community setting, Scandinavian researchers conducted a prospective, multicenter study involving 745 patients (mean age, 29.7). Patients underwent clinical staging at time of orchiectomy; absence or pr…